Recruiting Intergroup trials coordinated by the EORTC

Protocol
Title
Coordinating Group
1203INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

Study Coordinator:

Anna Dorothea Wagner, Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

EORTC Gastrointestinal Tract Cancer Group
1206A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)

Study Coordinator:

Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

EORTC Head and Neck Cancer Group
130110-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Study Coordinator:

Pierre W. Wijermans, HagaZiekenhuis - locatie Leyweg, 'S Gravenhage - Den Haag

Michael Luebbert, Universitaetsklinikum Freiburg, Freiburg

Gerwin Huls, Radboud University Medical Center Nijmegen, Nijmegen

EORTC Leukemia Group
1307A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.

Study Coordinator:

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

David Cameron, Western General Hospital, Edinburgh

Judith Balmana, Hospital General Vall D'Hebron, Barcelona

Nicholas Turner, Royal Marsden Hospital - Chelsea, London, London

Nicholas Turner, Institute Of Cancer Research, Sutton

EORTC Breast Cancer Group
1333A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Study Coordinator:

Bertrand Tombal, Cliniques Universitaires Saint-Luc, Brussels

EORTC Genito-Urinary Cancers Group
1401Management of low risk ductal carcinoma in situ (low-risk DCIS): a randomized, multicentre, non-inferiority trial, between standard therapy approach versus active surveillance

Study Coordinator:

Pieter Wesseling, Radboud University Medical Center Nijmegen, Nijmegen

Jelle Wesseling, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam

EORTC Breast Cancer Group
1409A prospective Colorectal Liver Metastasis DataBase with an Integrated Quality Assurance program

Study Coordinator:

Serge Evrard, Institut Bergonie, Bordeaux

Graeme Poston, Royal Liverpool University Hospital, Liverpool

EORTC Gastrointestinal Tract Cancer Group
1416A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy

Study Coordinator:

Mary O'Brien, Royal Marsden Hospital - Chelsea, London, London

EORTC Lung Cancer Group
1419Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma

Study Coordinator:

Michael Weller, UniversitaetsSpital Zurich, Zurich

EORTC Brain Tumor Group
1527Diffusion-Weighted Magnetic REsonance Imaging Assessment of Liver Metastasis and Improve Surgical Planning

Study Coordinator:

Serge Evrard, Institut Bergonie, Bordeaux

EORTC Gastrointestinal Tract Cancer Group
62113A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Study Coordinator:

Isabelle Ray Coquard, Centre Leon Berard, Lyon

EORTC Soft Tissue and Bone Sarcoma Group